Valeant Pharma (VRX): Yet Another Guidance Cut - Jefferies

November 9, 2016 7:40 AM EST
Get Alerts VRX Hot Sheet
Price: $15.00 -0.73%

Rating Summary:
    10 Buy, 12 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 34 | New: 34
Trade VRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Valeant Pharmaceuticals (NYSE: VRX) but cut his price target nearly in half to $22 from $40. While Q3 revs of $2.444B were just slightly (0.7%) below his est, EPS came in well below consensus ($1.55 vs $1.75) due to product mix & higher interest expense.

However, guidance was the focal point and lowered once again. The analyst thinks the biggest surprise was management's commentary that FY17 revs & EBITDA will be lower than current FY16 guidance. Management claims divestitures are not needed to maintain liquidity but will likely be key to NT performance.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $14.98 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Earnings

Related Entities

Jefferies & Co

Add Your Comment